Skip to main content
. 2015 Jan 7;33(2):290–299. doi: 10.1007/s10637-014-0203-5

Fig. 5.

Fig. 5

Comparison of doxorubicin drug synergy between cytochalasin B and 21, 22-dihydrocytochalasin B against P388/ADR leukemia assessed by log surviving fraction cloning assays. a Cloning assay for concomitant DiHCB/ADR treatment. b Cloning assay for concomitant CB/ADR treatment. Concomitant treatments were administered at varying concentrations for 3 h